Joint Formulary & PAD

Delgocitinib - Hand eczema

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Cream
Associated Icons :
Restrictions / Comments :
Important

Dermatology specialist teams only.

PAD Profile

ChemicalSubstance :
Delgocitinib
Indication :
Hand eczema
Group Name :
Keywords :
CHE
Brand Names Include :
Anzupgo
Important Information :

FIRE HAZARD-: product contains cetostearyl alcohol. Advise patients not to smoke or go near naked flames because of risk of severe burns

Latest Additions Date From :
13 Feb 2026
Latest Additions Date To :
13 Mar 2026
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed that delgocitinib for the treatment of Chronic Hand Eczema (CHE) is implemented in line with NICE TA1107.

RED traffic light status for delgocitinib for CHE was agreed.

Prescribing should be initiated and continued by a specialist clinician. If the patient has already been initiated on this medicine by a specialist clinician, please ensure this is recorded as a ‘Hospital Only Drug’ in the patient’s medication list, in order to be alert to potential side-effects and interactions with other medicines prescribed in primary care

Other Indications

Below are listed other indications that Delgocitinib is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Hand eczema.